Guangzhou-based Yichenyun Health (伊辰云健康) received +10M RMB in Series A round of financing led REDHILL CAPITAL (丹麓资本) and supported by Chuangyu Mingchen (创钰铭晨) and TSINGYUAN VENTURES I LP, VCbeat.top reported.
Yichenyun Health, which took the second prize in a recent Guangzhou biomedical start-up contest(http://news.southcn.com/gd/content/2020-07/18/content_191184849.htm), is specialized in catheter-related bloodstream infection (CRBSI), the presence of bacteremia originating from an intravenous catheter. It is one of the most frequent, lethal, and costly complications of central venous catheterization and also the most common cause of nosocomial bacteremia, according to https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093967/
China reported 4 million hospital-acquired infections and the direct economic loss ranged from 11,299 yuan to 33,187 yuan, data in 2015 showed.( https://vcbeat.top/OWY5M2Q5OTkxNTVlMDVmZmRhNzY4NTIzOWQ5ZDRjMzk=)
The company’s CEO Jiang Qiongcheng (蒋琼橙, Jenny) said CRBSI increased hospital stay, medical cost and death rate. It’s estimated the CRBSI market reached $40 billion in the world and $6-10 billion in China, with an annual growth rate of 12 percent.
